In a report released yesterday, Paul Matteis from Stifel Nicolaus maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $420.00. The company’s shares closed yesterday at $418.82.
According to TipRanks, Matteis is a 4-star analyst with an average return of 7.5% and a 46.65% success rate. Matteis covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Alkermes, and ACADIA Pharmaceuticals.
In addition to Stifel Nicolaus, Vertex Pharmaceuticals also received a Hold from Maxim Group’s Naz Rahman in a report issued on May 7. However, on the same day, Piper Sandler assigned a Buy rating to Vertex Pharmaceuticals (NASDAQ: VRTX).
The company has a one-year high of $448.40 and a one-year low of $320.01. Currently, Vertex Pharmaceuticals has an average volume of 1.04M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vertex Pharmaceuticals (VRTX) Company Description:
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
Read More on VRTX:
- Vertex Pharmaceuticals price target raised to $477 from $466 at UBS
- Vertex Pharmaceuticals price target raised to $529 from $511 at Leerink
- Vertex Pharmaceuticals price target raised to $424 from $417 at RBC Capital
- Vertex Pharmaceuticals price target raised to $456 from $450 at Piper Sandler
- Vertex Pharmaceuticals affirms FY4 revenue view of $10.55B-$10.75B
